Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

53.24 -2.97 (-5.28%)
Streaming Delayed Price Updated: 1:02 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 614,226
Open 57.06
Bid (Size) 53.25 (100)
Ask (Size) 53.49 (300)
Prev. Close 56.21
Today's Range 53.24 - 57.90
52wk Range 27.66 - 76.61
Shares Outstanding 93,706,790
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗
Via Chartmill

Performance

YTD
+14.6%
+14.6%
1 Month
-3.2%
-3.2%
3 Month
+19.4%
+19.4%
6 Month
+61.0%
+61.0%
1 Year
-27.3%
-27.3%

More News

Read More
News headline image
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Pricing of $550 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte's Chief Technical Ops Officer Sells Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
These 3 Stocks Are Using Buybacks to Signal Market Confidence ↗
Via MarketBeat
News headline image
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown ↗
Via Benzinga
Topics Bonds
News headline image
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗
Via Benzinga
News headline image
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Vaxcyte (PCVX) Q2 Loss Widens 11% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Vaxcyte, Inc. - Common Stock publicly traded?
Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
What exchange does Vaxcyte, Inc. - Common Stock trade on?
Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
What is the current price of Vaxcyte, Inc. - Common Stock?
The current price of Vaxcyte, Inc. - Common Stock is 53.24
When was Vaxcyte, Inc. - Common Stock last traded?
The last trade of Vaxcyte, Inc. - Common Stock was at 03/13/26 01:02 PM ET
What is the market capitalization of Vaxcyte, Inc. - Common Stock?
The market capitalization of Vaxcyte, Inc. - Common Stock is 4.99B
How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
Vaxcyte, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.